Study of Serum Haptoglobin and Its Glycoforms in the Diagnosis of Hepatocellular Carcinoma: A Glycoproteomic Approach
- 23 August 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 5 (10) , 2691-2700
- https://doi.org/10.1021/pr060109r
Abstract
Increased serum haptoglobin concentration and changes in its glycosylation have been reported in certain cancer types. Information for hepatocellular carcinoma (HCC) has not yet been available. In this study, we aimed to carry out a systematic analysis of serum concentrations of haptoglobin (Hp) and its glycoforms in the patients with HCC and noncancer patients only with chronic liver diseases (CLD) and to examine their clinical values. This study was divided into two major parts, (1) measurement of serum Hp concentration, and investigation of its value in the diagnosis of HCC, and (2) quantitative analysis of Hp glycoforms with alpha-2,6-sialylation and/or alpha-1,6-fucosylation by using lectin affinity purification and 2D gel electrophoresis and investigation of their relationships with tumor stage. The concentrations of serum Hp in HCC patients were significantly higher than those in noncancer patients with CLD. With the use of serum concentrations of Hp and alpha-fetoprotein, a logistic regression (LR) model was developed from the training data set and used to classify the validation cases. At a specificity of 95%, the sensitivity for HCC detection was 79%. Comparing serum concentrations of alpha-2,6-sialylated Hp (S-Hp) and alpha-1,6-fucosylated Hp (F-Hp) between HCC and CLD patients suggests that purification of S-Hp and F-Hp could enrich the glycosylation variants associated with HCC. 2D gel analysis of S-Hp and F-Hp identified a total of 18 glycoforms. A unique pattern of Hp glycoforms comprising both hypersialylated fucosylated and hyposialylated fucosylated species was found in the HCC patients. Serum concentrations of these glycoproteins were significantly higher in the patients with advanced tumors, suggesting their tumor-specific nature. We have shown that serum Hp is a potential biomarker in the diagnosis of HCC. The combined use of Hp and AFP could greatly improve the diagnostic accuracy. A unique pattern of Hp glycoforms with altered sialylation and fucosylation is specific to HCC and associated tumor progression.Keywords
This publication has 20 references indexed in Scilit:
- Haptoglobin: Retrospectives and PerspectivesPublished by Taylor & Francis ,2020
- Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancerBritish Journal of Cancer, 2004
- Increased arterial expression of a glycosylated haptoglobin isoform after balloon dilationCardiovascular Research, 2003
- The acute phase protein haptoglobin is locally expressed in arthritic and oncological tissuesInternational Journal of Experimental Pathology, 2003
- Nitric oxide synthesis is involved in arterial haptoglobin expression after sustained flow changesFEBS Letters, 2002
- Haptoglobin Polymorphism and Body Iron Storescclm, 2002
- Gene expression of α1-6 fucosyltransferase in human hepatoma tissues: A possible implication for increased fucosylation of α-fetoproteinHepatology, 1998
- 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver diseaseBritish Journal of Cancer, 1997
- Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancerBritish Journal of Cancer, 1989
- Elevated levels of abnormally-fucosylated haptoglobins in cancer seraBritish Journal of Cancer, 1987